ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2740

Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases

Martina Skácelová1, Gabriela Gabčová2, Pavel Horak3, Zuzana Mikulková2, František Mrázek4, Eva Kriegová5 and Andrea Smržová6, 1III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, 2Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic, 3III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, 4Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, 5Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, 6III. Department of Internal Medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, B cells, Cyclophosphamide and vasculitis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although cyclophosphamide (CFA) remain the cornerstone for treatment of patients with severe manifestations of systemic autoimmune diseases, the knowledge about the effect of CFA on circulating cell populations in these diseases is limited.

Objectives: To investigate the effect of CFA administration on circulating immune cell subpopulations in patients with vasculitis and autoimmune systemic diseases.

Methods: We analysed major immune cell populations in peripheral blood (PB) from 13 patients (vasculitis n=7; autoimmune systemic diseases n=6). Paired samples from each patient were analysed before CFA administration, and after one and six months’ follow-up. Using 6-colour flow cytometer (BD FACSCanto II) we characterized T lymphocytes (CD3, CD4, CD8, CD25, CD127, HLA-DR), B lymphocytes (CD19, CD20, CD27, HLA-DR), NK cells (CD3, CD16, CD56, CD69), neutrophils (CD15, CD11b, CD16, CD54, CD62L, CD64), and monocytes (CD11b, CD14, CD16, CD64, HLA-DR). Statistics was done by software GraphPad Prism.

Results: After single dose of CFA, the percentage of CD69+ NK cells increased and CD4+/CD8+ ratio decreased compared with their percentage before administration (P=0.01; P=0.03, respectively). After six months of CFA administration, decreased percentage of activation marker HLA-DR on CD4+ cells (P=0.004), decreased percentage of CD19+ B cells (P=0.04) and increased percentage of activation marker CD69 on NK cells (P=0.004) was observed comparing with paired samples obtained before CFA therapy. Different patterns were observed in subgroups of patients with vasculitis and autoimmune systemic diseases. Clinical evaluation of treatment response and observed changes in immune cell populations in individual patients is ongoing.

Conclusion: In our patients, CFA therapy resulted in changes of activation markers on CD4+, CD8+, B and NK cells, as well as neutrophils. Further investigation of selected markers may lead to identification of new biomarkers for prediction of the treatment effectiveness.

Acknowledgement: MZ CR VES15-28659A, IGA_LF_2017_009


Disclosure: M. Skácelová, None; G. Gabčová, None; P. Horak, None; Z. Mikulková, None; F. Mrázek, None; E. Kriegová, None; A. Smržová, None.

To cite this abstract in AMA style:

Skácelová M, Gabčová G, Horak P, Mikulková Z, Mrázek F, Kriegová E, Smržová A. Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cyclophosphamide-treatment-modulates-circulating-cell-populations-in-patients-with-vasculitis-and-autoimmune-systemic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cyclophosphamide-treatment-modulates-circulating-cell-populations-in-patients-with-vasculitis-and-autoimmune-systemic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology